Grogg: Leading Release Therapeutics' Journey to Clinical Success
Portfolio - People | Jan 30, 2025 | EIN
Release Therapeutics, a privately held Swiss BioMedTech company, has appointed Dr. Julien Grogg as its new CEO. Grogg, who previously served as COO, takes the helm to guide the company through a transformative phase, focused on advancing its encapsulated cell technology into clinical development. The tech, designed to treat metachromatic leukodystrophy (MLD), aims at overcoming the blood-brain barrier to deliver therapeutic proteins to the CNS. This follows a successful non-human primate study, validated by RTx’s Scientific Advisory Board which showcased an encouraging safety profile for the technology. As Release Therapeutics prepares for Series A financing and IND application, CEO Grogg emphasizes the company's commitment to providing solutions for children affected by MLD, underscoring that every day counts in their mission to improve treatments for this devastating disorder.
Sectors
- BioMedTech
- Pharmaceuticals and Biotechnology
Geography
- Switzerland – Release Therapeutics is based in Geneva, Switzerland, making it the primary geographical context for the activities and operations discussed in the article.
- France – The Paris Brain Institutes Innovation Unit for Gene and Cell Therapy, based in France, collaborated with Release Therapeutics on pivotal research, making France relevant to the article.
Industry
- BioMedTech – The article is centered on Release Therapeutics, a company classified within the BioMedTech industry, which focuses on creating advanced biomedical technologies to treat conditions like metachromatic leukodystrophy.
- Pharmaceuticals and Biotechnology – Release Therapeutics' work developing a therapeutic platform for CNS disorders fits within the Pharmaceuticals and Biotechnology industry, emphasizing innovative biotech solutions for genetic diseases.
Financials
- Series A Financing – RTx is preparing for Series A financing to support the transition from the bench towards clinical trials.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Release Therapeutics | Target Company | Companies | A Swiss BioMedTech company focused on developing therapies for genetic diseases of the CNS. |
| Julien Grogg | CEO | People | Newly appointed CEO of Release Therapeutics, responsible for leading the company into its next phase of clinical development. |
| Paris Brain Institutes Innovation Unit for Gene and Cell Therapy (GENOV) | Scientific Collaborator | Companies | Worked alongside RTx in developing the encapsulated cell therapy for MLD. |
| Thomas Mehrling | Outgoing CEO | People | Former CEO of Release Therapeutics who contributed to its foundational growth. |
| Clarence Peter | Chairman of the Board | People | Chairman of Release Therapeutics' board, endorsing the appointment of the new CEO. |